What is the ROCE (Return on Capital Employed) of Exelixis this year?
The ROCE of Exelixis is 0.08 undefined this year.
Exelixis ROCE 2024
Exelixis ROCE
0.08
Ticker
EXEL
ISIN
US30161Q1040
WKN
936718
In 2024, Exelixis's return on capital employed (ROCE) was 0.08, a -6.78% increase from the 0.08 ROCE in the previous year.
Exelixis Aktienanalyse
What does Exelixis do?
Exelixis Inc. is a biopharmaceutical company that specializes in researching and developing drugs for various types of cancer. The company was founded in 1994 and is headquartered in Alameda, California. It has brought several drugs to the market over the years that have had a positive impact on thousands of patients. The company's founders, Corey Goodman, George Scangos, and John Walker, previously worked at Genentech and decided to start their own company to focus on cancer research and drug development. Exelixis Inc. has had numerous successes since its inception, including the development of Cabozantinib, a drug used to treat various types of cancer such as thyroid cancer, kidney cancer, and advanced prostate cancer. The company also has several drug candidates in clinical testing. Its business model revolves around researching and developing drugs that target proteins and signaling pathways overactivated in cancer cells. Exelixis Inc. often collaborates with other companies in the pharmaceutical industry to share development costs and risks. The company is divided into different divisions to treat various cancer types, including kidney, liver, thyroid, and lung cancer. One of its significant milestones was the approval of Cabozantinib by the FDA in 2012 for the treatment of advanced kidney and thyroid cancer. The drug has since been approved in other countries and has been successful in treating different types of cancer. Exelixis Inc. is dedicated to developing better and more effective cancer drugs to help patients. It works closely with doctors, researchers, and other pharmaceutical companies to constantly explore new approaches to combat cancer cells. In summary, Exelixis Inc. is a leading player in the research and development of drugs for various types of cancer. It has a track record of approved drugs and a pipeline of innovative drug candidates. The company's goal is to help cancer patients and contribute to improving people's health. Exelixis ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROCE Details
Unraveling Exelixis's Return on Capital Employed (ROCE)
Exelixis's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.
Year-to-Year Comparison
Analyzing Exelixis's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.
Impact on Investments
Exelixis's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.
Interpreting ROCE Fluctuations
Changes in Exelixis’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.
Frequently Asked Questions about Exelixis stock
How has the ROCE (Return on Capital Employed) of Exelixis developed compared to the previous year?
The ROCE of Exelixis has increased by -6.78% decreased compared to the previous year.
What does a high ROCE (Return on Capital Employed) mean for investors of Exelixis?
A high Return on Capital Employed (ROCE) indicates that Exelixis has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.
What does a low ROCE (Return on Capital Employed) mean for investors of Exelixis?
A low ROCE (Return on Capital Employed) can indicate that Exelixis has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.
How does an increase in ROCE from Exelixis impact the company?
An increase in the ROCE of Exelixis can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.
How does a reduction in the ROCE of Exelixis affect the company?
A decrease in ROCE of Exelixis can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.
What are some factors that can influence the ROCE of Exelixis?
Some factors that can affect Exelixis's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.
Why is the ROCE of Exelixis so important for investors?
The ROCE of Exelixis is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.
What strategic measures can Exelixis take to improve the ROCE?
To improve the ROCE, Exelixis can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.
How much dividend does Exelixis pay?
Over the past 12 months, Exelixis paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Exelixis is expected to pay a dividend of 0 USD.
What is the dividend yield of Exelixis?
The current dividend yield of Exelixis is .
When does Exelixis pay dividends?
Exelixis pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Exelixis?
Exelixis paid dividends every year for the past 0 years.
What is the dividend of Exelixis?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Exelixis located?
Exelixis is assigned to the 'Health' sector.
Wann musste ich die Aktien von Exelixis kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Exelixis from 7/31/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/31/2024.
When did Exelixis pay the last dividend?
The last dividend was paid out on 7/31/2024.
What was the dividend of Exelixis in the year 2023?
In the year 2023, Exelixis distributed 0 USD as dividends.
In which currency does Exelixis pay out the dividend?
The dividends of Exelixis are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Exelixis
Our stock analysis for Exelixis Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Exelixis Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
